Drug intelligence / Profile preview

SAGE-904

Development stage: Phase 1
Lead developer: Sage Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SAGE-904 is a small molecule drug developed by Sage Therapeutics as a positive allosteric modulator of the N-methyl-D-aspartic acid (NMDA) receptor. It was designed as an oral therapy for disorders associated with NMDA hypofunction, which are implicated in various neurological and neuropsychiatric conditions. SAGE-904 has a differentiated pharmacologic and pharmacokinetic profile compared to other NMDA receptor modulators from the same developer. The drug reached Phase 1 clinical trials in healthy volunteers but its development was discontinued prior to completion of these studies[1][3][4][5].

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on SAGE-904.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAGE-904.

Explore the full profile